Company

Affimed

As of the edition of 20 October 2026, Affimed runs 5 drugs; it is on route A at 6 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

Route A at 6 targets, route B at 0 targets.

Three of its 6 rows, by target and route
Target	Route
FCGR3A Low affinity immunoglobulin gamma Fc region receptor III-A	Route A
IL3RA Interleukin-3 receptor subunit alpha	Route A
ADRA1D Alpha-1D adrenergic receptor	Route A

In the product

6 company-target rows on route A or B; 3 are not shown here, and no score is.